ReviewPopulation Differences in Major Functional Polymorphisms of Pharmacokinetics/pharmacodynamics-related Genes in Eastern Asians and Europeans: Implications in the Clinical Trials for Novel Drug Development
References (394)
- et al.
Effect of VKORC1-1639 GhA polymorphism, body weight, age, and serum albumin alterations on warfarin response in Japanese patients
Thromb. Res.
(2009) - et al.
Pharmacokinetic and pharmacodynamic variation associated with VKORC1 and CYP2C9 polymorphisms in Thai patients taking warfarin
Drug Metab. Pharmacokinet.
(2010) - et al.
Investigation of allele and genotype frequencies of CYP2C9, CYP2C19 and VKORC1 in Iran
Pharmacol. Rep.
(2010) - et al.
Linkage between the CYP2C8 and CYP2C9 genetic polymorphisms
Biochem. Biophys. Res. Commun.
(2002) - et al.
Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population
Biochem. Biophys. Res. Commun.
(1999) - et al.
Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population
Pharmacol. Res.
(2004) - et al.
Biological definition of multiple chemical sensitivity from redox state and cytokine profiling and not from polymorphisms of xenobiotic-metabolizing enzymes
Toxicol. Appl. Pharmacol.
(2010) - et al.
Genetic variations and haplotypes of CYP2C19 in a Japanese population
Drug Metab. Pharmacokinet.
(2005) - et al.
CYP2C19 genetic polymorphism in Thai
Burmese and Karen populations. Drug Metab. Pharmacokinet.
(2006) - et al.
Association of poor metabolizers of cytochrome P450 2C19 with head and neck cancer and poor treatment response
Mutat. Res.
(2008)
Effective global drug development strategy for obtaining regulatory approval in Japan in the context of ethnicity-related drug response factors
Clin. Pharmacol. Ther.
(2010)
Clinical development and review times for new drugs in Japan: associated factors
Clin. Pharmacol. Ther.
(2010)
PMDA’s challenge to accelerate clinical development and review of new drugs in Japan
Clin. Pharmacol. Ther.
(2010)
Exploring differences in drug doses between Japan and Western countries
Clin. Pharmacol. Ther.
(2010)
Genetic Polymorphisms and Haplotypes of Major Drug Metabolizing Enzymes in East Asians and Their Comparison with Other Ethnic Populations
Cur. Pharmacogenomics
(2007)
Clinical consequences of cytochrome P450 2C9 polymorphisms
Clin. Pharmacol. Ther.
(2005)
Genetic variations of CYP2C9 in 724 Japanese individuals and their impact on the antihypertensive effects of losartan
Hypertens. Res.
(2008)
Genetic variation in metabolizing enzyme and transporter genes: comprehensive assessment in 3 major East Asian subpopulations with comparison to Caucasians and Africans
J. Clin. Pharmacol.
(2010)
Genetic analysis of CYP2C9 polymorphism in a Japanese population
Pharmacogenetics
(1997)
Genetic polymorphism of cytochrome P450s, CYP2C19, and CYP2C9 in a Japanese population
Ther. Drug Monit.
(1998)
Pharmacokinetics/genotype associations for major cytochrome P450 enzymes in native and first- and third- generation Japanese populations: comparison with Korean, Chinese, and Caucasian populations
Clin. Pharmacol. Ther.
(2008)
Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients
Clin. Pharmacol. Ther.
(2003)
Frequency of cytochrome P450 2C9 mutant alleles in a Korean population
Br. J. Clin. Pharmacol.
(2001)
Allele and genotype frequencies of CYP2C9 in a Korean population
Br. J. Clin. Pharmacol.
(2005)
Frequency of CYP2C9 variant alleles, including CYP2C9*13 in a Korean population and effect on glimepiride pharmacokinetics
J. Clin. Pharm. Ther.
(2011)
CYP2C9*3 allelic variant is associated with metabolism of irbesartan in Chinese population
Eur. J. Clin. Pharmacol.
(2005)
Frequency of cytochrome P450 2C9 allelic variants in the Chinese and French populations
Fundam. Clin. Pharmacol.
(2003)
Genetic polymorphisms of cytochrome P450 enzymes 2C9 and 2C19 in a healthy Mongolian population in China
Genet. Mol. Res.
(2010)
A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity
Hum. Mol. Genet.
(2005)
The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism
Pharmacogenetics
(1996)
Prevalence of CYP2C9 and VKORC1 mutation in patients with valvular heart disease in northern Thailand
J. Med. Assoc. Thai.
(2009)
Genetic polymorphism of CYP2C9 in a Vietnamese Kinh population
Ther. Drug Monit.
(2005)
CYP2C9 polymorphism: prevalence in healthy and warfarin-treated Malay and Chinese in Malaysia
Singapore Med. J.
(2009)
Malaysian Indians are genetically similar to Caucasians: CYP2C9 polymorphism
J. Clin. Pharm. Ther.
(2006)
Genetic factors associated with patient-specific warfarin dose in ethnic Indonesians
BMC Med. Genet.
(2011)
CYP2C9 and CYP2C19 genetic polymorphisms: frequencies in the south Indian population
Fundam. Clin. Pharmacol.
(2005)
Frequencies of VKORC1 -1639 GhA, CYP2C9*2 and CYP2C9*3 genetic variants in the Northern Indian population
Biosci. Trends
(2010)
Impact of CYP2C9 genetic polymorphism on warfarin dose requirements in Pakistani population
Pak. J. Pharm. Sci.
(2010)
Genotype frequencies of selected drug metabolizing enzymes and ABC drug transporters among breast cancer patients on FAC chemotherapy
Basic Clin. Pharmacol. Toxicol.
(2010)
Genetic polymorphisms of cytochrome P450 enzymes 2C9 and 2C19 in a healthy Iranian population
Clin. Exp. Pharmacol. Physiol.
(2007)
Allele frequency of CYP2C9 gene polymorphisms in Iran
Thromb. Haemost.
(2002)
Influence of CYP2C9 and VKORC1 Polymorphisms on Warfarin and Acenocoumarol in a Sample of Lebanese People
J. Clin. Pharmacol.
(2011)
Pharmacogenetics of Coumarin Dosing: Prevalence of CYP2C9 and VKORC1 Polymorphisms in the Lebanese Population
Genet. Test. Mol. Biomarkers
(2011)
Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin
Br. J. Clin. Pharmacol.
(1999)
Linkage disequilibrium between the CYP2C19*17 allele and wildtype CYP2C8 and CYP2C9 alleles: identification of CYP2C haplotypes in healthy Nordic populations
Eur. J. Clin. Pharmacol.
(2010)
Polymorphism of CYP2D6, CYP2C19, CYP2C9 and CYP2C8 in the Faroese population
Eur. J. Clin. Pharmacol.
(2005)
The Influence of CYP2C9 and VKORC1 Gene Polymorphisms on Optimal Warfarin Doses After Heart Valve Replacement
Medicina (Kaunas)
(2011)
Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide
Br. J. Cancer
(2010)
Validation of a new fluorogenic real-time PCR assay for detection of CYP2C9 allelic variants and CYP2C9 allelic distribution in a German population
Br. J. Clin. Pharmacol.
(2002)
VKORC1 -1639GhA and CYP2C9*3 are the major genetic predictors of phenprocoumon dose requirement
Eur. J. Clin. Pharmacol.
(2010)
Cited by (211)
A harmonisation approach to traditional Chinese medicine registration in Asian countries
2024, Journal of Traditional Chinese Medical SciencesDetermination of single-molecule transport activity of OATP2B1 by measuring the number of transporter molecules using electrophysiological approach
2023, Journal of Pharmacological SciencesApplications of human induced pluripotent stem cell and human embryonic stem cell models for substance use disorders: Addiction and neurodevelopmental toxicity
2022, Novel Concepts in iPSC Disease ModelingPharmacogenetics in psychiatry: study of allelic variants of CYP450 in chilean patients with psychiatric disease
2022, Revista Medica Clinica Las Condes
This study was supported in part by the program for the Promotion of Fundamental Studies in Health Sciences from the National Institute of Biomedical Innovation, by a Health and Labour Sciences Research Grant from the Ministry of Health, Labour and Welfare in Japan, by the Japan Health Sciences Foundation (Research on Publicly Essential Drugs and Medical Devices), and by KAKENHI (23390144, 23790611) from the Japan Society for the Promotion of Science (JSPS).
Copyright © 2012 The Japanese Society for the Study of Xenobiotics. Published by Elsevier Ltd. All rights reserved.